mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2019-4-99-103mrj-966Research ArticleКЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИCLINICAL GUIDELINESВакцинация против желтой лихорадки при ревматических заболеванияхVaccination against yellow fever in rheumatic diseasesБеловБ. С.BelovB. S.

Белов Борис Сергеевич

115522, Москва, Каширское шоссе, 34А

Boris Sergeevich Belov

34A, Kashirskoe Shosse, Moscow 115522

belovbor@yandex.ruТарасоваГ. М.TarasovaG. M.

115522, Москва, Каширское шоссе, 34А

V.A. Nasonova Research Institute of Rheumatology

МуравьеваН. В.MuravyevaN. V.

115522, Москва, Каширское шоссе, 34А

V.A. Nasonova Research Institute of Rheumatology

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation20192310201913499103Copyright © Белов Б.С., Тарасова Г.М., Муравьева Н.В., 20192019Белов Б.С., Тарасова Г.М., Муравьева Н.В.Belov B.S., Tarasova G.M., Muravyeva N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/966

Желтая лихорадка (ЖЛ) – облигатное трансмиссивное природно-очаговое инфекционное заболевание, характеризующееся полиорганным поражением и высокой летальностью. Интенсификация международных связей и туристических потоков, в том числе в эндемичные по ЖЛ регионы, в последние годы существенно повысила значение вакцинопрофилактики данной инфекции у больных с иммунологическими нарушениями, в том числе с ревматическими заболеваниями (РЗ), получающих иммуносупрессивную терапию. В связи с этим представляют большой интерес недавно опубликованные рекомендации экспертов Бразильского общества ревматологов, посвященные эффективности и безопасности иммунизации против ЖЛ у пациентов с хроническими иммуноопосредованными воспалительными заболеваниями (включая РЗ). Основные положения этих рекомендаций представлены в настоящей публикации.

Yellow fever (YF) is an obligate, transmissible, feral herd infectious disease characterized by multiple organ dysfunction and high mortality rates. The intensification of international relations and tourist flows, including those to the YF endemic areas in recent years has substantially increased the value of vaccination against this infection in patients on immunosuppressive therapy for immunological disorders, including rheumatic diseases (RDs). In this connection, the recently published guidelines by the experts of the Brazilian Society of Rheumatology on the efficiency and safety of immunization against YL in patients with chronic immune-mediated inflammatory diseases (including RDs) are of great interest. The main provisions of these guidelines are presented in this paper.

желтая лихорадкавакцинацияревматические заболеванияyellow fevervaccinationrheumatic diseasesReferencesFurer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2019 Aug 14. pii: annrheumdis-2019-215882. doi: 10.1136/annrheumdis-2019-215882. [Epub ahead of print]Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2019 Aug 14. pii: annrheumdis-2019-215882. doi: 10.1136/annrheumdis-2019-215882. [Epub ahead of print]Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016 Jan; 68(1):1-26. doi: 10.1002/art.39480. Epub 2015 Nov 6.Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016 Jan; 68(1):1-26. doi: 10.1002/art.39480. Epub 2015 Nov 6.Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014 Feb;58(3):e44-100. doi: 10.1093/cid/cit684. Epub 2013 Dec 4.Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014 Feb;58(3):e44-100. doi: 10.1093/cid/cit684. Epub 2013 Dec 4.Staples JE, Monath TP, Gershman MD, Barrett ADT.Yellow fever vaccines. In: Plotkin SA, Orenstain WA, Offi PA, Edvards KM, editors. Plotkin's vaccines.7th ed. Philadelphia: Elsevier; 2018. P. 1191-1265.Staples JE, Monath TP, Gershman MD, Barrett ADT.Yellow fever vaccines. In: Plotkin SA, Orenstain WA, Offi PA, Edvards KM, editors. Plotkin's vaccines.7th ed. Philadelphia: Elsevier; 2018. P. 1191-1265.Whittembury A, Ramirez G, Hernandez H, et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine. 2009 Oct 9;27(43):5974-81. doi: 10.1016/j.vaccine.2009.07.082.Whittembury A, Ramirez G, Hernandez H, et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine. 2009 Oct 9;27(43):5974-81. doi: 10.1016/j.vaccine.2009.07.082.World Health Organization. Vaccine safety basics, vodule 2^types of vaccine and adverse reactions. http://vaccine-safety-training.org/overview-and-outcomes-2.html.World Health Organization. Vaccine safety basics, vodule 2^types of vaccine and adverse reactions. http://vaccine-safety-training.org/overview-and-outcomes-2.html.Scheinberg M, Guedes-Barbosa LS, Mangueira C, et al. Yellow fever revaccination during infliximab therapy. Arthritis Care Res (Hoboken). 2010 Jun;62(6):896-8. doi: 10.1002/acr.20045Scheinberg M, Guedes-Barbosa LS, Mangueira C, et al. Yellow fever revaccination during infliximab therapy. Arthritis Care Res (Hoboken). 2010 Jun;62(6):896-8. doi: 10.1002/acr.20045Kerneis S, Launay O, Ancelle T, et al. Safety and immunogenicity of yellow fever 17D vaccine in adults receiving systemic corticosteroid therapy: an observational cohort study. Arthritis Care Res (Hoboken). 2013 Sep; 65(9):1522-8. doi: 10.1002/acr.22021.Kerneis S, Launay O, Ancelle T, et al. Safety and immunogenicity of yellow fever 17D vaccine in adults receiving systemic corticosteroid therapy: an observational cohort study. Arthritis Care Res (Hoboken). 2013 Sep; 65(9):1522-8. doi: 10.1002/acr.22021.Wieten RW, Jonker EF, Pieren DK, et al. Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccines receiving immunosuppressive medication. Vaccine. 2016 Mar 4;34(10):1247-51. doi: 10.1016/j.vaccine.2016.01.037.Wieten RW, Jonker EF, Pieren DK, et al. Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccines receiving immunosuppressive medication. Vaccine. 2016 Mar 4;34(10):1247-51. doi: 10.1016/j.vaccine.2016.01.037.Porudominsky R, Gotuzzo EH. Yellow fever vaccine and risk of developing serious adverse events: a systematic review. Rev Panam Salud Publica. 2018 Jun 5;42:e75. doi: 10.26633/RPSP.2018.75.Porudominsky R, Gotuzzo EH. Yellow fever vaccine and risk of developing serious adverse events: a systematic review. Rev Panam Salud Publica. 2018 Jun 5;42:e75. doi: 10.26633/RPSP.2018.75.Pileggi GS, Da Mota LMH, Kakehasi AM, et al. Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immunemediated inflammatory diseases. Adv Rheumatol. 2019 Apr 29;59(1):17. doi: 10.1186/s42358-019-0056-x.Pileggi GS, Da Mota LMH, Kakehasi AM, et al. Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immunemediated inflammatory diseases. Adv Rheumatol. 2019 Apr 29;59(1):17. doi: 10.1186/s42358-019-0056-x.Gershman MD, Staples JE. Yellow fever. https://cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/yellow-fever.htm.Gershman MD, Staples JE. Yellow fever. https://cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/yellow-fever.htm.Ferreira CC, Campi-Azevedo AC, Peruhype-Magalhaes V, et al. Impact of synthetic and biological immunomodulatory therapy on the duration of 17DD yellow fever vaccine-induced immunity in rheumatoid arthritis. Arthritis Res Ther. 2019 Mar 14; 21(1):75. doi: 10.1186/s13075-019-1854-6.Ferreira CC, Campi-Azevedo AC, Peruhype-Magalhaes V, et al. Impact of synthetic and biological immunomodulatory therapy on the duration of 17DD yellow fever vaccine-induced immunity in rheumatoid arthritis. Arthritis Res Ther. 2019 Mar 14; 21(1):75. doi: 10.1186/s13075-019-1854-6.Nascimento Silva JR, Camacho LA, Siqueira MM, et al. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine. 2011 Aug 26; 29(37):6327-34. doi: 10.1016/j.vaccine.2011.05.019/Nascimento Silva JR, Camacho LA, Siqueira MM, et al. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine. 2011 Aug 26; 29(37):6327-34. doi: 10.1016/j.vaccine.2011.05.019/Staples JE, Bocchini JA Jr, Rubin L, et al. Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015 Jun 19;64(23):647-50.Staples JE, Bocchini JA Jr, Rubin L, et al. Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015 Jun 19;64(23):647-50.Domingo C, Yactayo S, Agbenu E, et al. Detection of yellow fever 17D genome in urine. J Clin Microbiol. 2011 Feb;49(2):760-2. doi: 10.1128/JCM.01775-10.Domingo C, Yactayo S, Agbenu E, et al. Detection of yellow fever 17D genome in urine. J Clin Microbiol. 2011 Feb;49(2):760-2. doi: 10.1128/JCM.01775-10.CDC. Transfusion-related transmission of yellow fever vaccine virus-California, 2009. MMWR Morb Mortal Wkly Rep. 2010 Jan 22;59(2):34-7.CDC. Transfusion-related transmission of yellow fever vaccine virus-California, 2009. MMWR Morb Mortal Wkly Rep. 2010 Jan 22;59(2):34-7.CDC. Transmission of yellow fever vaccine virus through breast-feeding – Brazil, 2009. MMWR Morb Mortal Wkly Rep. 2010 Feb 12;59(5):130-2.CDC. Transmission of yellow fever vaccine virus through breast-feeding – Brazil, 2009. MMWR Morb Mortal Wkly Rep. 2010 Feb 12;59(5):130-2.

The authors declare that there are no conflicts of interest present.